Want to see IL:INCR full AI Analyst Report?
INCR Stock Chart & Stats
514.20
>-0.01(-0.10%)
At close: 4:00 PM EST
514.20
>-0.01(-0.10%)
Day’s Range― - ―
52-Week Range225.30 - 605.00
Previous CloseN/A
Volume249.40K
Average Volume (3M)91.19K
Market Cap
₪176.97M
Enterprise Value283.64M
Total Cash (Recent Filing)₪46.67M
Total Debt (Recent Filing)₪183.01M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding59,228,558
10 Day Avg. Volume173,192
30 Day Avg. Volume91,185
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash-generation ReboundA return to positive free cash flow in 2025 signals improved operational discipline and working-capital management. Durable cash generation reduces dependence on external financing, supports reinvestment or deleveraging, and materially lowers liquidity risk if the trend persists over multiple quarters.
Manageable LeverageA sub-0.5 debt-to-equity ratio provides financial flexibility for a growth or restructuring path. Improved leverage cuts interest burden and preserves borrowing capacity, enabling the company to fund capex or strategic initiatives without immediate equity dilution if profitability recovery continues.
Vertically Integrated ModelOwning cultivation through retail creates control over supply, quality and margin capture. Vertical integration supports product development, branded commercialization and channel diversification, which are structural advantages for sustained market share and resilience against single-channel disruptions.
Bears Say
Persistent LossesThree consecutive years of negative ROE and ongoing net losses indicate the company is not yet generating returns on invested capital. This erodes shareholder equity over time, limits reinvestment capacity, and raises the bar for management to deliver a sustained, structural profit turnaround.
Compressed MarginsMaterial gross margin compression undermines core profitability and suggests either pricing pressure, higher input costs, or unfavorable mix. Without margin restoration, top-line growth is less able to translate into sustainable earnings, weakening long-term free-cash-flow prospects.
Cash-flow VolatilityA sharp swing from large outflows to positive FCF highlights volatility in cash conversion. Such volatility raises execution risk: if working-capital or pricing dynamics revert, the company may face renewed funding needs or margin stress, impairing the durability of the 2025 improvement.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was 225.30 and its highest was 605.00 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is ₪176.97M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is Aug 17, 2026 which is in 31 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -62.8 earnings per share for the quarter, missing the consensus estimate of N/A by -62.8.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 59,228,558 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -62.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.696%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in IL:INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to production, marketing, and distribution of medical cannabis products. The company's product line features dried cannabis flowers and an oil-based cannabis extract. Additionally, InterCure allocates investments to the biomedical sector. Established in 1994, the firm's main headquarters are situated in Herzliya, Israel.